ViaCyte Appoints Michael Yang President and CEO and Provides Company Update
- Michael Yang appointed President and CEO and to Board of Directors
- Brittany Bradrick promoted to COO and CFO, and Steve White appointed CTO
- Actively recruiting patients into Phase 2 clinical trials for PEC-Encap and PEC-Direct; supports timeline for topline data in 2H 2021 and 1H 2022, respectively
- Company expands cell manufacturing capacity to support its current programs and research for new therapeutic indications
News provided by
Share this article
, a clinical-stage regenerative medicine company, today announced the appointment of Michael Yang to President and CEO and as a member of ViaCyte s Board of Directors. The Company also appointed Steve White, BSc Pharm, as Chief Technology Officer, and promoted Brittany Bradrick, who joined ViaCyte in July 2020 as Chief Financial Officer (CFO), to Chief Operating Officer (COO) and CFO. These executive leadership team appointments come as the Co